Description
TMP920 is a highly potent and selective RORγt antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC 50 of 0.03 µMIn VitroTMP920 (0.09-30 µM) starts to show toxic effects on cell growth at >10 µM in Naïve CD4 + T cells. TMP920 suppresses Th17 cell differentiation and lost its IL-17 inhibitory effect at <2.5 µM in vitro. TMP920 suppresses IL-17 production from differentiated Th17 cells in vitro. TMP920 suppresses the Th17 cell transcriptome and promotes alternate T-cell subsets. TMP920 significantly reduces RORγt-DNA interactions. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity AssayCell Line: Naïve CD4 + T cells Concentration: 0.09-30 µM Incubation Time: 48 hours Result: Has toxic effects on cell growth at >10 µM.Form:SolidIC50& Target:IC50: 0.03 µM (RORγt)